Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
25 juin 2020 08h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be...
Novan to Present at Virtual Life Sciences Investor Forum on June 25
24 juin 2020 08h15 HE
|
Novan, Inc.
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive...
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
30 avr. 2020 16h05 HE
|
Novan, Inc.
Enrollment of first patient targeted for September 2020Top line results expected late in the second quarter of 2021 based on anticipated timeline MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE)...
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
20 avr. 2020 16h05 HE
|
Novan, Inc.
Engages H.C. Wainwright & Co. as strategic and financial advisorNITRICIL™ nitric oxide technology platform has enabled multiple early and late-stage pipeline opportunities in dermatology, women’s...
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
03 avr. 2020 08h15 HE
|
Novan, Inc.
Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
23 mars 2020 08h15 HE
|
Novan, Inc.
Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including...
Novan Provides SB206 Program and Business Update
06 févr. 2020 08h30 HE
|
Novan, Inc.
FDA grants Type C meeting for SB206 to be held on April 1, 2020Last subject completes last visit, Week 24 safety evaluationAdditional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb....
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
02 janv. 2020 16h15 HE
|
Novan, Inc.
Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern TimeFocus of call: top-line efficacy data and sensitivity analyses MORRISVILLE, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) --...
Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology
08 oct. 2019 08h30 HE
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical...
Novan Hires Michelle Patterson as Vice President of Project Management
03 sept. 2019 16h05 HE
|
Novan, Inc.
Underscores Company’s preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results...